# A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)

> **NCT07734610** · PHASE1 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (estimated)

## Conditions studied

- Severe Renal Impairment
- Healthy

## Interventions

- **DRUG:** Nemtabrutinib

## Key facts

- **NCT ID:** NCT07734610
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-08
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734610, "A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*